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Abstract: Like any other drug, antimicrobial drugs are prone to pharmacokinetic drug 
interactions. These drug interactions are a major concern in clinical practice as they may 
have an effect on efficacy and toxicity. This article provides an overview of all published 
pharmacokinetic studies on drug interactions of the commonly prescribed antimicrobial 
drugs oxazolidinones, rifamycines, macrolides, fluoroquinolones, and beta-lactams, 
focusing on systematic research. We describe drug-food and drug-drug interaction studies 
in humans, affecting antimicrobial drugs as well as concomitantly administered drugs. 
Since knowledge about mechanisms is of paramount importance for adequate management 
of drug interactions, the most plausible underlying mechanism of the drug interaction is 
provided when available. This overview can be used in daily practice to support the 
management of pharmacokinetic drug interactions of antimicrobial drugs.  
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Antimicrobial drugs manifest a wide variety of drug interactions, which can differ greatly in their 
extent of severity and clinical relevance. Not only co-medication, but also food and herbal medicine 
can interact with antimicrobial drugs and vice versa. The nature of these interactions can be of 
pharmacodynamic (PD) and/or pharmacokinetic (PK) origin.  
A PD interaction consists of an alteration of a pharmacological response, through either agonism or 
antagonism, without affecting the kinetics of the drug. In cases of PD interactions, physicians are 
advised to re-evaluate the benefit-risk ratio of the co-prescribed drug for each individual patient [1]. 
PK interactions result in an altered disposition of a drug within a patient and can take place at the level 
of each of four processes influencing drug exposure, i.e., absorption, distribution, metabolism, and 
excretion, commonly described by the acronym ADME. Historically, the relevance of drug 
distribution, particularly of protein binding, has been over-emphasized in the assessment of drug 
interactions, and nowadays the main cause of drug-drug interactions has been recognized to be 
modulation of the activity, i.e., inhibition or induction, of cytochrome P450 (CYP) enzymes and 
transporters.  
Clinicians, prescribing the drug and pharmacists—often involved in medication review, therapeutic 
drug monitoring (TDM), or consultation on drug choice or dose—should be aware of clinically 
relevant interactions between antimicrobial drugs and co-medication, herbal medicine, and/or food in 
order to avoid toxicity, side effects, or inadequate treatment. PK interactions are in most cases 
manageable by adjusting the dose and by monitoring of drug levels (TDM) or vital signs. This review 
article will address PK interactions of antimicrobial drugs. The scope is to present an overview of PK 
studies on drug-drug and drug-food interactions of commonly prescribed antimicrobial drugs in daily 
clinical practice, i.e., oxazolidinones, rifamycines, macrolides, fluoroquinolones, and β-lactam 
antimicrobial drugs.  
2. Experimental Section 
The Pubmed database was searched for PK interaction studies on drug-drug and drug-food 
interactions of antimicrobial drugs (Figure 1). The search was limited through the following selections: 
“Humans”, “Clinical Trial”, “Randomized Controlled Trial”, “Comparative Study”, and “Controlled 
Clinical Trial”. Only articles written in English were included. Per group of antimicrobial drugs, a 
separate search was conducted consisting of the name of the group, the name of the individual drugs, 
and the term “drug interaction”. When the Medical Subject Heading (MeSH) term “drug interaction” 
was used, indented terms such as “Herb-Drug Interaction” and “Food-Drug Interaction” were also 
searched. The search terms “NOT in vitro” and “NOT review” were added since this review focuses on 
original articles of studies with human subjects. Summaries of product characteristics or package 
leaflets were not consulted since these sources will only present a snapshot of the available information 
and will therefore not give a good overall impression of their use in clinical practice.  
 




Figure 1. Scope of the review and summary of the experimental section. The gray area 
symbolizes the focus of this review, i.e., pharmacokinetic (PK) drug interactions of 
antimicrobial drugs. Arrows symbolize a PK interaction. Upwards pointing arrows (↑): 
interaction affecting antimicrobial drug (§3.x.1 “Antimicrobial drugs as victims”). 
Downwards pointing arrows (↓): interaction affecting co-prescribed drug (§3.x.2 
“Antimicrobial drugs as perpetrators”).  
 
When a search resulted in only a few results, the query was expanded with the criterion “Case 
Report” and explicitely marked as such in this review since its contents have to be interpreted carefully 
because of the limited level of evidence. 
All searches were conducted in March and April 2011. The relevant results were described per 
group of antimicrobial drugs. For each group, the drug interactions are divided into interactions 
affecting the antimicrobial drugs and interactions effecting the co-medication. The drug that is affected 
is identified by the term ‘victim’ and the drug that causes the effect by ‘perpetrator’. A table 
summarizing the most important drug interactions is provided for each group of antimicrobial drugs. 
3. Results and Discussion  
3.1. Oxazolidinones  
Currently, LZD is the only oxazolidinone authorized by the European Medicines Agency (EMA) 
and the US Food and Drug Administration (FDA). The number of properly designed  
drug-interaction studies with oxazolidinones is limited and the underlying mechanisms of some drug 
interactions are not yet fully elucidated. Furthermore, there is a lack of reviewed publications on drug 
interactions of newer compounds such as PNU-100480, posizolid (AZD2563), radezolid (RX-1741), 
torezolid and others, several of which are still being studied in phase I, II or III clinical research. A 
summary of LZD PK interactions is provided in Table 1. 




Table 1. Summary of interactions of the oxazolidinone LZD with enzyme systems and/or food. 
 Absorption Metabolism: Excretion: 
 Fat meal Antacids CYP P-gp Reactive Oxygen Species 
LZD ↓ = - S*2 = 
*1 Arrows pointing downward (↓) indicate inhibition and upward (↑) induction. The number of arrows indicates the 
extent of the inhibition or induction: 1 arrow <50%, 2 arrows 50–150%, 3 arrows >150% increase/decrease of AUC. 
“S” indicates the drug being a substrate, and “=” interaction is not relevant. 
*2 Mostly based on case reports: in need of further research. 
Note: Systematic research on newer compounds such as PNU-100480, posilozid (AZD2563), radezolid (RX-1741), 
torezolid, and others is not available. 
Since there were no interactions affecting displacement/distribution this process was not included in the table. 
3.1.1. Oxazolidinones as Victims 
Antimicrobial drugs: In an open-label comparative study of 8 healthy volunteers receiving 600 mg 
of both LZD and rifampicin (RIF) intravenously, a reduction of LZD plasma concentration was 
observed [2]. An in vitro study demonstrated that LZD is not detectably metabolized by human CYP 
and did not inhibit the activities of human CYP isoforms 1A2, 2C9, 2C19, 2D6, 2E1, or 3A4 [3]. 
Based on these observations along with the fact that RIF is a well-known P-gp inducer, the authors 
suggest LZD to be a P-gp substrate [2]. This hypothesis was further supported by a case report of a 
patient with MDR-TB. This patient received LZD and clarithromycin (CLR), a potent inhibitor of P-gp 
and a well-known CYP3A4 inhibitor. It was shown that co-administration of CLR with LZD resulted 
in a markedly increased LZD AUC [4].  
The combination of aztreonam and LZD in an open-label cross-over study that included 13 healthy 
volunteers resulted in a statistically significant, although probably not clinically relevant increase of 
LZD AUC of approximately 18% [5]. The authors suggest that the mechanism for this interaction is 
partly explained by a common elimination pathway, i.e., renal excretion. However, the definite 
mechanism remains unknown. 
Food and antacids: In a two-phase single-dose open-label cross-over study of 12 healthy 
volunteers, a fatty meal caused a small but statistically significant reduction of mean LZD plasma 
concentration [6]. The Cmax decreased by 23% and tmax increased from 1.5 hours to 2.2 hours, probably 
due to prolonged gastric residence time. An open-label cross-over study in 28 healthy volunteers tested 
the hypothesis that a disturbed balanced of reactive oxygen species might lower the in vivo clearance 
of LZD by supplementing dietary antioxidants, i.e., vitamin C and E, but concluded there was no 
significant effect on LZD Cmax and AUC [7]. This is in line with current literature indicating that 
supplemented antioxidant vitamins have subtle effects on in vivo reactive oxygen species balance [7]. 
A randomized open-label cross-over study of 17 healthy volunteers showed that the antacid Maalox 
has no effect on the PK of LZD [8]. 
3.1.2. Oxazolidinones as Perpetrators 
Serotonin reuptake inhibitors: A single randomized controlled trial (RCT) [9] and several case 
reports [10–23] describe LZD’s potential for drug interactions due to its reversible monoamine 
oxidase-A inhibitor activity. In case reports, serotonic toxicity was observed after co-administration of 




LZD with drugs that influence serotonin levels like selective serotonin reuptake inhibitors (SSRIs), 
tricyclic antidepressants, monoamine oxidase inhibitors, and other serotonergic agents such as 
citalopram, diphenhydramine, duloxetine, fluoxetine, paroxetine, sertraline, trazodone, and 
venlafaxine. However, one case report presented a depressed patient receiving co-administered 
mirtazepine and LZD being treated successfully without toxic signs [24]. The RCT focused on the PK 
interaction of LZD with the over the counter (OTC) sympathomimetic drugs pseudoephedrine and 
phenylpropanolamine. A slight increase in blood pressure and a minimal effect on the PK of both  
co-administered drugs was found in 42 healthy individuals [9]. The serotonin reuptake inhibitor 
dextromethorphan was co-administered with LZD with no clinical effect: only a slight decrease of 
dextrorphan, the primary metabolite of dextromorphan, was observed [9]. 
3.2. Rifamycines  
The antimicrobial group of rifamycines exhibits their bactericide effect through inhibition of 
bacterial DNA-dependant RNA polymerases. The most pronounced members of the group, 
rifampi(ci)n (RIF), rifabutin (RFB) and rifapentine (RFP), are often administered for the treatment of 
Mycobacterium tuberculosis, leprosy (Hansen’s disease), and M. avium complex. A summary of the 
interactions is presented in Table 2.  
Table 2. Summary of interactions of rifamycines with enzyme systems and/or food. 
 Rifamycines *1 
 RIF RFB RFP Rifalazil, rifaximin 
Absorption:     
Fat meal ↓ - - ↓-↓↓ 
Antacids 0 - - - 
OATP ↓↓-↑ - - - 
Metabolism: -    
CYP1A2 ↑-↑↑ - - - 
CYP2B6 ↑ - - - 
CYP2C8 ↑-↑↑ - - - 
CYP2C9 ↑-↑↑ - - - 
CYP2J2 ↑ - - - 
CYP3A4 S, ↑-↑↑↑ S, ↑-↑↑↑ - 0 
UGT1A1 ↑-↑↑ 0-↑ - - 
Excretion:     
P-gp ↑-↑↑ - - - 
*1  Arrows pointing downward (↓) indicate inhibition and upward (↑) induction. The number of arrows indicates the 
extent of the inhibition or induction: 1 arrow < 50%, 2 arrows 50–150%, 3 arrows >150% increase/decrease of AUC. 
“S” indicates the drug being a substrate, “0” indicates the absence of an interaction. 
*2 Inhibition after single dose, upregulation after multiple doses. 
Since there were no interactions affecting displacement/distribution this process was not included in the table. 




3.2.1. Rifamycines as Victims 
Antiretroviral drugs: Amprenavir co-administered with RFB or RIF in a randomized prospective 
cohort study that included 24 healthy subjects resulted in a 293% increase of RFB AUC, but had no 
effect on RIF kinetics [25]. The authors suggest amprenavir both to be a CYP3A4 inhibitor and 
substrate and RFB as a CYP3A4 substrate being a less potent inducer of CYP3A4 than RIF. Indinavir, 
a potent inhibitor of CYP3A4, increased the RIF mean AUC by 73% in HIV-infected patients [26]. 
When the RFB dose was decreased from 300 mg/day to 150 mg/day and the indinavir dose was 
increased from 2400 mg/day to 3000 mg/day, the combination produced similar indinavir PK 
parameters but an increase of RFB AUC by 70% [27]. Another study showed that when 300 mg RFB 
was added to indinavir 2400 mg/day, AUC exposure to RFB significantly increased by 273% [28]. 
Nelfinavir increased the AUC of RFB by approximately 22% in a prospective cohort of seven 
tuberculosis patients [29]. RFB AUC increased by 44% and Cmax by 45% after co-administration with 
saquinavir and was well tolerated in a randomized open-label study of HIV-infected patients [30].  
Co-administration of tenofovir disoproxil fumarate and RIF resulted in no significant changes in PK 
parameters [31]. Atazanavir co-administration with RIF resulted in an increased RIF exposure by  
160–250% [32]. Co-administration of didanosine with RFB resulted in unchanged RFB exposure [33].  
Antifungal drugs: Fluconazole had little [34] to no [35] effect on RIF PK parameters. However, 
fluconazole did increase RFB AUC by 82% and its metabolite LM565 by 216%, possibly through 
inhibition of CYP3A [36]. Posaconazole caused the AUC of RFB to increase by 72% and the Cmax by 
31%, also possibly through CYP3A4 inhibition [37]. 
Antimicrobial drugs: CLR was found to increase RIF AUC by 60% [38] and RFB AUC by 76–99% 
in two studies [39,40]. Co-trimoxazole increased the median AUC of RIF by 60% and Cmax by 31% 
[41]. The bioavailability of RIF was reduced by approximately 32% when co-administered with 
isoniazide in a fixed dose combination capsule formulation of 450 mg RIF and 300 mg isoniazide, 
possibly caused by enhanced decomposition of RIF to the insoluble metabolite 3-formyl RIF SV in the 
gastrointestinal tract due to the presence of isoniazide in the acidic stomach [42]. The RFP exposure 
was reduced by co-administration with moxifloxacin (MXF), resulting in a decrease of RFP AUC by 
20.3% [43]. The authors explain this decrease by autoinduction of metabolism of RFP through high 
doses of RFP administered intermittently for more than two weeks. One study focused on the effect of 
pefloxacin on RIF PK and found that the AUC of RIF in serum was increased by 200% [44]. In a 
randomized single-dose cross-over study of 16 tuberculosis patients, co-administration of RIF and 
isoniazide with or without pyrazinamide resulted in a significantly reduced AUC and Cmax of RIF [45].  
Food and antacids: A randomized cross-over study in 14 healthy subjects found that the antacid 
aluminum-magnesium did not alter PK parameters of RIF, but a high-fat meal did reduce the Cmax by 
36% and the AUC by a mere 6%, nearly doubling the tmax [46]. The effect of food intake on rifalazil 
PK parameters was studied in 12 healthy volunteers receiving a normal breakfast or a high-fat 
breakfast, with a fat content of respectively 30% or 60% of the total calories, resulting in a 
progressively increased exposure by 30% to 60% [47].  




3.2.2. Rifamycines as Perpetrators 
Antidiabetic drugs: The effect of RIF on antidiabetics such as gliclazide, glimepiride, and glyburide 
has been investigated in several studies. In a randomized cross-over study in nine healthy volunteers, 
RIF decreased the gliclazide AUC by 70% with clinically significant changed blood glucose levels 
[48]. The authors hypothesized that the decreased exposure was caused by induction of CYP2C9. A 
study with a similar design in 10 healthy subjects found the glimepiride exposure to decrease by 34% 
[49]. In a randomized open-label cross-over study, co-administering glyburide and a single intravenous 
dose of RIF demonstrated that RIF inhibited organic anion-transporter polypeptide (OATP) family 
members, which resulted in the glyburide AUC to decrease by 125% and Cmax by 81% [50]. In the 
same study multiple oral doses of RIF resulted in a decreased glyburide exposure, probably through 
induction of liver enzymes. In three cross-over studies of healthy volunteers RIF reduced repaglinide 
AUC by 31–81%, an effect probably caused by induction of CYP3A4 and possibly by CYP2C8. This 
resulted in changed blood glucose profiles [51–53]. RIF had no effect on PK parameters of diabecon 
(D-400), a complex herbal supplement supposedly offering glycemic control [54]. 
Antihistamines: RIF reduced the fexofenadine bioavailability through induction of intestinal P-gp, 
resulting in an increased oral clearance, calculated from dose/AUC, and a decrease of AUC [55]. RIF 
altered the disposition and antihistamine effect of ebastine, a non-sedative antihistamine, reducing the 
AUC of the active metabolite carebastine to 15% and reducing oral bioavailability [56]. The authors 
suggest that this might be caused by CYP3A4 induction, possibly combined with P-gp or  
CYP2J2 induction. 
HMG-coA reductase inhibitors (statins): RIF reduced exposure to atorvastatin by 80%, probably by 
CYP3A4 induction [57]. A recent study in 12 healthy Asian volunteers found that a single dose of RIF 
increased pravastatin AUC0-∞ by 182%, possibly through inhibited hepatic uptake by OATPs and 
inhibited biliary excretion mediated by MRP2 [58]. However, a multiple-dose study in 10 healthy 
Caucasian volunteers found that the pravastatin AUC was reduced by 31% [59]. This difference might 
be explained by up-regulation of mRNA of drug transporters, e.g., OATP and CYP3A4, after multiple 
doses of RIF or possibly by different polymorphism of Asians compared to Caucasian volunteers. RIF 
had no effect on the mean AUC of rosuvastatin (95.8%), although in some patients a marked decrease 
was noted [60]. The authors suggest that OATP1B1 transporter expression might vary, resulting in 
variable intracellular RIF concentration and interpatient variability in AUC. RIF greatly decreased the 
AUC of simvastatin by 87%, possibly by CYP3A4 mediated first pass effect in the liver and intestinal 
wall [61]. In a randomized open-label 2-way cross-over study of 10 healthy subjects, pretreatment with 
600 mg RIF reduced the 8 mg single-dose rosiglitazone AUC by 65% and Cmax by 33%, probably 
through induction of CYP2C8 and, to a lesser extent CYP2C9 [62]. RIF reduced the pioglitazone AUC 
significantly by 54%, without a significant effect on Cmax, probably via induction of CYP2C8 enzyme 
system [63]. RIF had a similar effect on nateglinide, reducing the AUC by 24% without affecting  
the Cmax [64].  
Immunosuppressants: Several interaction studies co-administering rifamycins with 
immunosuppressants have been conducted. In a small study of four patients, RIF significantly 
decreased cyclosporine A serum trough concentrations through induction of CYP450 enzyme mediated 
metabolism [65]. A cross-over study in 12 healthy volunteers receiving RIF and everolimus found a 




reduced everolimus Cmax by 58%, AUC by 63%, and a reduced t1/2 from 32 to 24 hours [66].  
Co-administration of RIF with mycophenolic acid (MPA) was investigated in a prospective cohort PK 
interaction study following 8 stable renal allograft recipients [67]. A decreased MPA AUC by 17.5% 
was observed, with an increased exposure to the glucuronidated metabolites. This suggested an 
induction of uridine diphosphate glucuronosyltransferase (UGT), resulting in increased MPA 
glucuronidation which possibly also was due to RIF-associated increased expression of MRP2. The 
authors hypothesized that RIF competitively inhibits MRP2-mediated transport of MPA, inhibiting the 
enterohepatic recirculation. RIF appeared to induce both intestinal and hepatic metabolism of 
tacrolimus by means of induction of CYP3A and P-gp in the liver and small bowel, resulting in a 
decreased bioavailability by 35%, along with an increased clearance [68]. RIF had no effect on PK of 
temsirolimus in healthy volunteers, but resulted in a decrease of Cmax by 36%, and did reduce the 
sirolimus AUC by 65% and Cmax by 56% [69]. 
Anti-retroviral drugs: Amprenavir co-administered with RFB in a randomized prospective cohort 
study that included 24 healthy subjects resulted in no change in amprenavir PK, whereas in the same 
study the combination of RIF and amprenavir resulted in a decrease of amprenavir AUC by 82% [25]. 
Atazanavir combined with RIF was examined in two studies. One study found a minor increase of 
atazanavir AUC of 10% but a decrease of the Cmin by 59%. This is clinically relevant as Cmin is the 
relevant PK parameter predicting anti-retroviral activity [32]. The second study, combining 
atazanavir/ritonavir with RIF, was terminated after patients encountered adverse events (i.e., vomiting 
and elevated transaminaseelevations levels) [70]. RFB increased darunavir/ritonavir exposure by 
approximately 60% [71]. Delavirdine was studied with both RFB and RIF in 12 HIV-positive patients. 
RIF co-administration resulted in a 2700% increase of oral clearance, leading to nearly negligible 
delavirdine concentrations [72]. RFB increased the oral clearance by 500% [73]. Co-administration of 
didanosine with RFB resulted in a 20% AUC increase of didanosine [74]. Combining RIF with 
enfuvirtide had no effect on enfuvirtide PK [75]. Efavirenz and RIF co-administration was studied in a 
non-blinded randomized PK study, resulting in a decrease in mean efavirenz Cmax by 24% and AUC by 
25% [76]. Other studies found either an increase in AUC of 5% [77] or a non-significant difference in 
the Cmin [78]. When 700/100 mg fosamprenavir/ritonavir bid was combined with RFB, a dose 
reduction of RFB by 75% is advised based on a PK interaction study in healthy volunteers [79].  
Indinavir is indicated as a substrate of CYP3A4, and ritonavir a potent CYP inhibitor.  
Co-administration of RIF with indinavir-ritonavir resulted in an AUC decrease of indinavir by 87% 
and ritonavir by 94%, besides a decrease in rifamipicin exposure [80]. A study combining 600 mg RIF 
once a day and adjusted dose lopinavir/ritonavir tablets of 600/150 mg or 800/200 mg was terminated 
due to adverse events, e.g., elevated AST/ALT, nausea and vomiting [81]. When maraviroc 100 mg 
was combined with RIF, the AUC of maraviroc was decreased by 50% and the Cmax by 70%, probably 
through induction of CYP3A4 [82]. Doubling the maraviroc dose to 200 mg resulted in maraviroc 
exposure approaching pre-induction values. Co-administration of nevirapine with RIF resulted in a 
decreased AUC by 36% and Cmin by 32% in one study [83], and a reduced Cmin by 39% in another 
[84]. The possible explanation lies in the fact that nevirapine is a CYP3A4 and 2B6 substrate or 
possibly even a P-gp substrate. When raltegravir 400 mg was co-administered with RIF, the Cmin was 
decreased by 61% and the AUC by 40%. After doubling the raltegravir dose the effect of RIF on 
raltegravir dose was abolished, but the C12h still dropped by 53% compared to raltegravir alone, 




possibly by potent induction of UGT 1 family, polypeptide 1 (UGT1A1), and CYP3A4 [85]. RIF 
reduced the AUC of saquinavir when co-administered with soft-capsule saquinavir by 70% in healthy 
volunteers and by 46% in patients [86]. RFB had a similar effect, decreasing AUC by 47% in  
HIV-infected patients [30]. Co-administration of tipranavir/ritonavir with a single dose of RFB 
resulted in a 16% increase in tipranavir C12h in healthy subjects [87]. Tizanidine and RIF co-
administration in a blinded randomized cross-over trial of 10 healthy volunteers resulted in a decrease 
of tizanidine AUC by 54% and Cmax by 51%, probably mostly through CYP3A4 and to a lesser extent 
through CYP1A2 induction [88]. RFB was found to have no effect on safety and PK parameters when 
combined with zidovudine, and thus no effect on UGT1A1 [89,90]. RIF increased apparent oral 
clearance of zidovudine [91,92], resulting in a decrease of AUC by 47% [91]. The authors suggest the 
underlying mechanism is an enzyme-inducing effect of RIF on the glucuronidation of  
zidovudine [91–93]. 
Benzodiazepines: Rifaximin had no effect on PK parameters of midazolam, which is primarily 
metabolized by CYP3A4 [94]. RIF did have a significant effect on midazolam, decreasing the AUC by 
approximately 96% and clinically significantly reducing the PD effects [95,96]. Also triazolam, 
predominantly metabolized by CYP3A4, was affected by RIF, with a reduced AUC by 95% and Cmax 
by 88% in a randomized double-blinded cross-over study resulting in an ineffective triazolam 
treatment [97]. Two different studies found that RIF reduced the AUC of zolpidem by 73% and Cmax 
by 58% [98] and of zopiclone by respectively 82% and 71% [99], probably through  
CYP3A4 induction. 
Antimycotics: RIF was observed to both inhibit and induce caspofungin disposition, resulting in a 
reduced C24h by 14 to 31% after multiple RIF doses, and was found to exhibit a transient net inhibition 
before full induction of metabolism, leading to an elevated AUC of caspofungin by 61% on the first 
days of co-administration [100]. RIF reduced the fluconazole AUC by 22% [101]. An open-label 
single-dose study found RIF reduced the itraconazole AUC by 88% in healthy subjects and by 64% in 
HIV-infected patients [102]. Finally, the posaconazole AUC decreased by 49% and the Cmax by 43% in 
24 healthy volunteers receiving RFB co-medication, possibly through induction of the UGT enzyme 
system [37]. 
Antimicrobial drugs: No significant PK interaction was found between azithromycin (AZM) and 
RFB [103]. RFB was observed to decrease CLR AUC by 44%, but increased the AUC of its metabolite 
14-OH-CLR in a study including 34 patients [40]. RIF reduced the exposure to co-trimoxazole, i.e., a 
reduction of trimethoprim of 47% and of sulfamethoxazole of 23% [104]. A study combining 
doxycyclin with RIF found significantly lower doxycyclin levels, higher clearance, and a significantly 
reduced t1/2 and AUC [105]. Co-administering RFP with MXF resulted in a decrease in AUC of MXF 
by 17%, besides reducing RFP exposure [43]. When RIF was combined with MXF, the MXF AUC 
was reduced by 27–31% [106,107]. RIF caused a reduction of pefloxacin AUC by 27% when 
administered concomitantly [108]. In a three-way randomized cross-over design study, co-
administration of RIF with quinine resulted in an increase of unbound clearance, Clun, by 690% [109]. 
In a different study, RIF reduced the median AUC by 75% through induced metabolic clearance [110]. 
RIF has no effect on the AUC of dapsone, but increased dapsone clearance by 67% [111]. 
Hormones: Both rifalazil [112] and rifaximin [113] exhibited no effect on PK parameters of ethinyl 
estradiol after co-administration in healthy volunteers. A blinded randomized placebo-controlled, 




cross-over study of 19 healthy volunteers found the AUC of toremifene and of tamoxifen to be 
decreased by approximately 87% and the Cmax by 55% after co-administration with RIF [114]. 
Anti-hypertensive agents: In a randomized cross-over study of 12 healthy volunteers, RIF reduced 
the Cmax by 39% and the AUC by 56% [115]. A placebo-controlled cross-over study in 9 healthy 
subjects found that RIF had a minor effect on the PK of atenolol, evidenced by a decrease of AUC0-∞ 
to 81% and an increase of renal clearance to 109% [116]. RIF decreased talinolol AUC by 21% after 
intravenous and by 35% after oral administration, probably through increased P-gp mediated excretion 
[117]. For teratrolol, a 35% decrease of teratrolol AUC was caused by RIF [118]. Single oral dose RIF 
reduced the mean oral bioavailability of nifedipine to 36%, decreased the t1/2, and increased the total 
clearance, but had no effect on tmax and apparent Vd [119]. 
Anti-epileptics: RIF significantly decreased lamotrigine exposure in a blinded study in 10 healthy 
volunteers, probably due to an induction of the UGT enzyme system [120]. 
Psychopharmaca: The AUC of bupropion dropped by 43% when co-administered with RIF, 
through induction of CYP2B6 [121]. Haloperidol and RIF co-administration led to a decrease in 
haloperidol AUC to 30% of baseline by day 28, whereas cessation of RIF in patients receiving 
haloperidol and RIF resulted in higher haloperidol AUCs up to 329% at day 28 [122]. In a two-phase 
open-label cross-over study, RIF decreased risperidone AUC by 72% and Cmax by 50%, possibly 
through CYP3A4 induction [123]. A randomized placebo-controlled cross-over study of 6 healthy 
volunteers found the buspirone AUC to decrease by 91% and Cmax by 85%, without a significant effect 
on the main active metabolite piperazine but with a 35% increase of piperazine Cmax [124]. A similar 
effect on buspirone PK was observed in a different study, together with a significant reduction of effect 
of buspirone seen during 6 psychomotor tests, and attributed to a CYP3A4 interaction [125]. 
Anticoagulants: RIF enhanced clopidogrel-mediated platelet aggregation inhibition by 70%, 
possibly by induction of CYP3A4-mediated activation of clopidogrel [126]. RIF was found to 
significantly decrease prothrombin time and warfarin AUC [127]. 
Antihelmintic agents: Praziquantel was undetectable after a single dose of RIF in 7 of 10 subjects 
and in 5 of 10 after multi-dose administration, with the Cmax decreasing by 99% and 98% respectively 
and the AUC by 94% and 89% [128]. In the other subjects the effect was less distinct. 
Opioids: In a double-blinded randomized double-cross-over study of 10 healthy volunteers, RIF 
decreased the morphine AUC by 28% and the Cmax by 41% as well as those of the morphine 
metabolites, resulting in a loss of analgesic effect [129]. RIF greatly reduced oral and intravenous 
oxycodon AUC by respectively 53% and 86% and reduced oral bioavailability from 69% to 21% 
through induction of CYP3A4, attenuating the PD effect of oxycodon [130].  
Oncolytics: In a randomized cross-over study RIF reduced gefitinib AUC by 83% and Cmax by 65% 
through induction of CYP3A4 [131]. RIF mediated CYP3A induction, reduced imatinib mesylate 
AUC0–24h by 68%, AUC0-∞ by 74%, and Cmax by 54%, and increased imatinib metabolite  
exposure [132].  
Various: RIF increased atrasentan Cmax by 150% and reduced t1/2 by 77%, but had no effect on AUC 
[133] and decreased the AUC of deferasirox, an oral iron chelator, by 44% [134]. Mirodenafil, used to 
treat erectile dysfunctions, has been studied in an open-label 1-sequence 3-period cross-over study of 
19 healthy volunteers. It showed an RIF induced reduction of AUC of 97%, through CYP3A4 
induction [135]. Prednisolon AUC was lower after co-treatment with RIF [136]. In a blinded 4-period 




placebo-controlled cross-over study, 8 healthy volunteers were administered RIF and pentoxifylline, 
resulting in a 35% increase of pentoxifylline AUC [137]. The effect of RIF on hydrodolasteron, the 
active metabolite of dolasteron, PK was small, i.e., a reduction of AUC of 28% and a 17% reduction of 
Cmax [138]. The concentration and t1/2 of theophylline decreased significantly after co-administration 
with RIF and the clearance increased by 53% within a week [139].  
3.3. Macrolides  
Macrolides are thought to exert their action by inhibition of bacterial protein synthesis, by 
preventing peptyltransfyrase-controlled attachement of a peptyl to tRNA to a following amino acid. 
Interactions of macrolides with enzyme systems and the effect of food on the PK of macrolides are 
briefly summarized in Table 3. The articles on which the summary has been based are further specified 
in the text below. 
Table 3. Summary of interactions of macrolides with enzyme systems and/or food.  
 Macrolides *1 
 Azithromycin Clarithromycin Erythromycin Telithromycin Roxithromycin 
Absorption:      
Food 0, ↓↓↓*2 ↑ 0 0 - 
Antacids - ↓ - - - 
Grapefruit juice - 0*3 - - - 
P-gp - ↓↓ - - - 
Metabolism: - - - - - 
CYP2C19 - ↓↓↓ - - - 
CYP3A4 0 S, ↓-↓↓↓ ↓-↓↓↓ ↓↓ ↓ 
Excretion:      
P-gp ↓-↓↓ - - - - 
*1 Arrows pointing downward (↓) indicate inhibition and upward (↑) induction. The number of arrows indicates the extent 
of the inhibition or induction: 1 arrow < 50%, 2 arrows 50–150%, 3 arrows >150% increase/decrease of AUC.  
“S” indicates the drug being a substrate, “0” indicates the absence of an interaction 
*2 Absorption of capsules has been reduced, but absorption of tablets was unaffected by food. 
*3 No effect on clarithromycin PK, except for an increase in tmax. 
Since there were no interactions affecting displacement/distribution this process was not included in the table. 
3.3.1. Macrolides as Victims 
Anti-retroviral drugs: AZM has been suggested to be a substrate for P-gp. A two-way open-label 
cross-over study of 12 healthy volunteers receiving AZM co-administered with nelfinavir, an inhibitor 
of P-gp, caused the AZM Cmax and AUC to increase by more than 100% [140].  
Antihistamines: A randomized open-label cross-over study of 24 healthy individuals found an 
interaction between AZM and the antiallergic agent rupatadine. Despite an alteration of the Cmax of  
3-hydroxydesloratadine (i.e., metabolite of rupatadine), the PK parameters remained unchanged [141]. 
However, in a few studies a drug-drug interaction of AZM with antihistamines has been demonstrated. 
In a blinded randomized placebo-controlled study of 90 healthy patients receiving AZM and 
fexofenadine, the Cmax and AUC increased by 69% and 67%, respectively, by an unknown mechanism 




[142]. Co-administration of cimetidine with CLR resulted in a decrease of the Cmax of CLR and its 
metabolite 14-OH-CLR by 46% and 43% respectively. In addition, the tmax of 14-OH-CLR was 
prolonged from 1.39 to 2.34 hours (+68%) and the half life of both parent drug and metabolite 
increased, but neither AUC nor total clearance changed in this cross-over study (n = 12) [143].  
Anti-inflammatory drugs: An open-label study of 66 patients in which patients were randomly 
assigned to one of three groups, concluded that co-administration of piroxicam and AZM interfered 
negatively with periodontal disposition, possibly by displacement of piroxicam of local acceptor sites 
at the level of periodontal tissues [144]. 
Food: The lack of effect of nutritional state on AZM tablets, as well as on sachets and pediatric 
suspension, was previously shown in an open-label cross-over study of 12 healthy volunteers [145]. 
The effect of food on AZM capsules and tablets has been studied in a four-way randomized cross-over 
study of 8 healthy volunteers [146]. The observations made in this study suggest that AZM capsules, in 
contrast to tablets, exhibit slow and/or delayed disintegration in the fed stomach. Prolonged gastric 
acid exposure caused an increased des-cladinose AZM (DCA) AUC of 243% in fasted state versus 
270% in fed state. For CLR, a single dose cross-over design study showed that food intake directly 
before intake of a CLR tablet increased the extent of absorption by 25% and increased the AUC of the 
metabolite of CLR by approximately 9% [147]. An open-label cross-over study of 12 healthy 
volunteers showed that grapefruit juice, a well-known inhibitor of intestinal CYP3A4, had no effect on 
CLR PK parameters, except for an increased tmax [148]. For erythromycin (ERY) acistrate and 
enterocoated ERY bases the authors of a randomized cross-over study concluded that food intake had 
no effect on the PK of ERY acistrate and a slight effect on steady-state PK of the enterocoated ERY 
bases that might have some clinical relevance [149]. A single-phase open-label cross-over study in 18 
healthy volunteers showed no effect of food intake on telitromycin PK [150]. 
Proton pump inhibitors: An open-label cross-over study of 23 Helicobacter pylori-positive patients 
and negative controls found exposure to CLR to decrease when co-administered with lanzoprazole, 
resulting in a Cmax that decreased by respectively 40% and 15% and an AUC0–10h by respectively 30% 
and 10% [151]. 
Various: No effect on PK parameters was observed when intravenous AZM and ceftriaxon were  
co-administered [152]. An absence of clinically relevant and/or statistically significant changes in PK 
was observed when AZM was co-administered with atovaquone [153], ceftriaxon [152], chloroquine 
[154], dideoxyinosine [155], RFB (also no PK interaction with CLR) [156], terfenadine [157], and 
zidovudine (only an increase in tmax of 44%) [155].  
3.3.2. Macrolides as Perpetrators 
Anesthetics: A blinded randomized cross-over study of 10 healthy volunteers found an increase of 
the AUC of s-ketamine by 260% and the Cmax by 360% after pre-treatment with oral CLR, probably by 
inhibition of its CYP3A metabolism [158]. The s-ketamine drug effect increased, but other behavioural 
effects and cold pain scores remained unaffected. Ropivacaine co-administration, studied in a double-
blinded 3-way cross-over study in 8 healthy subjects, showed no changes in parent drug PK but a 
slight decrease in metabolite PK [159]. Administrating ERY with the local anesthetic lidocaine 
(lignocaine) has also been studied [160–162]. One study concluded that ERY either increases lidocaine 
metabolism to monoethylglycinexylidide (MEGX) or reduces further metabolism of MEGX, based on 




a 45–60% increase of MEGX AUC [162]. A subsequent study concluded that ERY increased the 
lidocaine AUC by 40–70% and the MEGX AUC by 40% [161]. 
Antiretroviral drugs: A comparative study showed that after combining the protease inhibitors 
tipranavir/ritonavir (TPV/r) with CLR the exposure of both TPV and CLR increased with 19% and 
66%, respectively. This increase was moderately tolerated but careful monitoring for signs of toxicity, 
especially at higher doses of CLR was required [87]. This study suggests that CLR is not just an 
inhibitor of CYP3A4 but also act as a substrate. The effect of co-administering CLR and amprenavir, 
both substrates of CYP3A4 isoenzymes, has been studied in 12 subjects in an open-label randomized 
multiple-dose three-period crossover study. CLR increased the AUC, Cmax and Cmin of amprenavir by 
respectively 18%, 15% and 39%, albeit not of clinical importance [163]. In a open-label multi-dose 
cross-over study in 33 HIV patients, co-administration of ERY and saquinavir (soft gelatin capsules) 
resulted in a 99% increase of saquinavir AUC0–8h [86]. 
Since antiretroviral drugs and macrolides are likely to be co-administered in patients with HIV and 
Mycobacterium infections, several studies focused on finding drug interactions between these two 
groups. An open-label randomized cross-over study in 22 patients focused on co-administration of 
CLR with ritonavir and found a small statistically significant increase of ritonavir exposure of 
approximately 10% [164]. A study with a similar design found a clinically non-significant effect of 
CLR on indinavir, i.e., indinavir Cmax increase of 58% and AUC of 47% in a smaller group of  
12 patients at steady state [165]. Co-administering a darunavir/ritonavir combination with CLR in a 
randomized open-label cross-over study in 18 healthy volunteers resulted in a small increase of 
darunavir AUC by 13% and Cmax by 17% [166]. During co-administration the CLR AUC increased by 
57% and the Cmax by 26%. In a RCT conducted on HIV patients AZM exhibited no effect on 
zidovudine PK, except for a decrease in tmax of 44%, suggesting both drugs can be co-administered 
safely [155]. A two-way open-label cross-over study of 12 healthy volunteers receiving AZM  
co-administered with nelfinavir caused the nelfinavir PK to decrease significantly, though not to be of 
clinical imporantance [140].  
HMG-coA reductase inhibitors (statins): CLR inhibits CYP3A4 mediated metabolism of several 
HMG-CoA reductase inhibitors such as atorvastatin, resulting in an increased AUC24h of 82–400% 
[167,168]. Other drugs from the same group, such as pravastatin (a non-CYP substrate), showed an 
increase of almost 200%, and, for simvastatin, a 1000% increase of the AUC [168]. Simvastatin [169] 
and rosuvastatin [170], both used to treat hypercholesterolemia, were studied in combination with 
ERY. ERY increased the simvastatin AUC by 620% and Cmax by 340%, whereas the rosuvastatin AUC 
decreased by 20% and Cmax by 30%. 
Proton pump inhibitors (PPIs): Co-administration of CLR with proton pump inhibitors (PPIs), such 
as esomeprazole [171], lansoprazole [151,172–175], omeprazole [176–179], pantoprazole [176], and 
rabeprazole [180]—a combination commonly prescribed as part of Helicobacter pylori treatment—has 
been investigated in several studies. A double-blinded RCT in 18 healthy volunteers of different 
genotype groups of CYP2C19 found an increase of approximately 110% of the AUC and Cmax of  
(S)-lansoprazole in extensive metabolizers (EMs) [172]. The increase was more pronounced in 
homozygous extensive metabolizers (homEMs) than in heterozygous extensive metabolizers (hetEMs). 
In poor metabolizers (PMs), CLR significantly increased the AUC and Cmax of lansoprazole. The 
authors suggest the mechanism of the interaction was CYP3A4 inhibiton [172]. Another double-




blinded RCT in 18 healthy Japanese volunteers found similar results [173]. Although the increase was 
slightly more pronounced in this study, the relative values between hetEMs, homEMs, and PMs were 
comparable. An 4-way cross-over RCT study in 12 H. pylori-negative volunteers looking into triple 
therapy consisting of lansoprazole, amoxicillin (AMX), and CLR compared to mono-therapy of each 
of the drugs found an increase of AUC of lansoprazole and 14-OH-CLR of 25% when co-administered 
as part of triple therapy [174]. No changes in AMX PK were found.  
Omeprazole has also been widely studied in combination with CLR [176–178]. In a randomized 
double-blinded cross-over study of 20 healthy volunteers, CLR increased omeprazole AUC by 90% 
but did not result in a significantly altered gastric pH [178]. The study did find increased CLR and  
14-OH-CLR levels in gastric tissue, i.e., 16% in gastric fundus and approximately 900% in gastric 
mucus. Another double-blinded randomized cross-over study focused on CLR and omeprazole in  
21 humans and found CLR to inhibit omeprazole metabolism, resulting in an increase of AUC of 
approximately 210% [177]. Also, a 200% increase was found in a randomized cross-over study  
co-administering esomeprazole and CLR to a group of 26 EMs and PMs [171]. A double-blinded 
cross-over study in 8 healthy volunteers not only studied co-administration of CLR with omeprazole, 
but also with pantoprazole, and found that the PK of CLR and pantoprazole remained unchanged. 
However, a twofold increase of omeprazole AUC and a decrease of omeprazole clearance and volume 
of distribution by respectively 75% and 56% was observed [176]. Rabeprazole, a proton pump 
inhibitor with minor CYP2C19 and 3A4 involvement, has been studied in a double-blinded RCT of  
19 healthy subjects. When co-administered with CLR the AUC of rabeprazole did not change 
significantly, but the AUC of rabeprazole thioether was found to exhibit an approximate 200% 
increase [180]. Administration of roxithromycin with co-medication lansoprazole [181] or  
omeprazole [181] resulted in unchanged PK parameters. 
Cardiovascular agents: In a prospective observational study combining CLR with digoxin, the 
digoxin clearance and elimination rate was 56–60% lower and the elimination half-life increased by 
82% after co-administration, as was suggested by several other case reports [182]. An open-label 
Latin-square design study of nine healthy volunteers found that co-administration of intravenous 
digoxin with either CLR or ERY did not lead to increased AUCs, but did lead to prolonged Clrenal by 
approximately 37% and urinary excretion of digoxin by 30%, for both CLR and ERY [183]. A study of 
8 Japanese heart failure inpatients resulted in a dose-dependent increase of digoxin concentration by 
70% at the common CLR dose of 400 mg per day [184]. A double-blinded cross-over study of  
12 healthy volunteers showed that oral administration of CLR 250 mg twice a day resulted in a 70% 
increase of digoxin AUC, whereas intravenous administration of digoxin combined with CLR caused a 
mere 20% increase of digoxin AUC. The authors suggest the increased oral bioavailability and reduced 
renal clearance to be caused by P-gp inhibition [185]. When sotalol was co-administered with 
telithromycin the sotalol Cmax decreased by 34% and AUC by 27%, leading to a decreased QTc 
interval by 15.5 ms [186]. Co-administration of ERY with talinolol resulted in a significant increase in 
talinolol AUC and Cmax [187], and co-administration with felodipine resulted in an increase of 
felodipine AUC and Cmax [188]. ERY was found to exhibit no effect on co-administered intravenous 
digoxine (except for a 1.4-fold increase of renal clearance) [183]. 
Antidiabetic drugs: In a randomized open-label cross-over study 12 healthy volunteers received 
glibenclamide and CLR, resulting in an increase of glibenclamide Cmax to 125% and AUC to 135%, 




possibly through inhibition of P-gp mediated transport [189]. In a 2x2 double-blinded randomized 
study, nine healthy subjects received single doses of tolbutamide with or without CLR, resulting in a 
20% increase of the tolbutamide absorption rate and a 26% increase of the mean bioavailability of 
tolbutamide [190]. As a result of simultaneous administration of tolbutamide and CLR, the authors 
reported a hypoglycemic effect. Co-administering ERY with glyburide resulted in an increase of 
glyburide Cmax by 18% and a tmax decrease from 4.9 to 3.0 hours but with minimal effect on serum 
glucose concentration [191]. 
Antihistamines: A randomized open-label cross-over study focused on co-administration of 
loratadine with CLR in 24 healthy volunteers and found no PK changes for CLR. However, increases 
were observed of loratadine Cmax by 36%, loratadine AUC of 76%, and increases in metabolite 
desloratadine AUC and Cmax, but no changes in QTc (<3%) [192]. The effect of AZM on older 
antihistamines has been researched in a randomized placebo-controlled study involving 18 volunteers. 
Small increases of less than 15% were found in desloratadine PK when co-administered with AZM, 
compared to an increase in fexofenadine Cmax of 69% and AUC of 67% [142]. In a retrospective cohort 
study, co-administration of oral ERY with antihistamines, especially terfenadine, was associated with 
an increased risk of QTc prolongation [193]. Another antihistaminic agent, fexofenadine, showed an 
increase in AUC of 60% after co-administration with ERY and an increase in tmax to 3h (instead of  
40 minutes) [194]. A lack of clinically relevant interaction was found between the antihistamine drug 
desloratadine and ERY, with an increase of desloratadine AUC of 10% and Cmax of 20% [195]. When 
loratadine was co-administered with ERY, an increase in loratadine AUC of 40% was found, without 
clinically relevant changes in safety profile [196]. 
Benzodiazepines: Since some macrolides inhibit oxidative hepatic metabolism of various drugs, 
several studies have been conducted with the combination of AZM and midazolam [197–200]. A total 
of 64 healthy volunteers were included in a double-blinded randomized trial comparing the effect of 
co-administration of midazolam with AZM or ERY. The authors concluded that ERY, and not AZM, 
enhanced the objective and subjective effects of midazolam via interference of AZM with the hepatic 
CYP3A metabolism of midazolam [200]. A double-blind 2-phase cross-over study of 10 healthy 
volunteers contradicts these findings, as no changes in PD or PK of midazolam were found except for 
a decrease in Cmax by 44% and a delay in tmax from 1.0 to 1.25 hours [199]. Two other open-label  
cross-over studies found no effect of AZM on midazolam PK or PD [197,198]. Co-administration of 
ERY with benzodiazepines has been investigated in several studies. For most benzodiazepines slight 
increases in AUC were measured, i.e., alprazolam 61% [201], diazepam 15% [202], flunitrazepam 
25% [202], nitrazepam 25% [203], triazolam by an uncalculated amount (Cmax increased significantly) 
[204], and zopiclone 40% [205]. However, temazepam PK remained unchanged [206]. Midazolam 
exhibited the largest changes in AUC, ranging from 230–400% [207,208]. Administration of 
roxithromycin with midazolam resulted in a slight increase of midazolam AUC by 47% and t1/2 from 
1.7 to 2.2 hours, accompanied by minor psychomotoric changes [209]. The authors suggest the 
midazolam PK changes to be caused by inhibition of CYP3A by roximycin. Intestinal and hepatic 
CYP3A inhibition by CLR resulted in a significant increase of midazolam AUC of 320% after 
intravenous administration and 800% after oral administration in an open-label comparative study of 
16 healthy volunteers [210]. 




Immunosuppressants: A less recent study found that ERY increased the bioavailability of 
cyclosporin A from 36% to 60% by enhanced absorption [211]. The Cmax and AUC of everolimus, a 
CYP3A4 substrate immunosuppressant, were increased by respectively 200% and 440% when  
co-administered with ERY [212]. An open-label placebo-controlled study of eight stable renal 
transplant patients found a 7% increase in AUC and 19% increase in Cmax of cyclosporine A, a 
CYP3A4 substrate, after co-administration of AZM, and concluded the drug-drug interaction not to be 
clinically significant [213]. No effect on PK parameters was observed when spiramycin was combined 
with cyclosporine A [214]. 
Antithrombotics: A study without detailed described methodology found that ERY attenuates 
platelet aggregation inhibition caused by clopidogrel, leading to an increase of 73% in platelet 
aggregation [126]. The authors suggest the underlying mechanism to be enhanced activation of 
clopidogrel by ERY via CYP3A4. Co-administration of roxithromycin with warfarin resulted in 
unchanged PK parameters [215]. 
Bronchodilators: Combining CLR with theophylline in a Latin-square design study of 8 patients did 
not result in any significant PK changes [216]. Several less recent studies focused on the effect of ERY 
on theophylline PK and found an increased t1/2. Patients receiving ERY may therefore have an 
additional risk for the development of theophylline toxicity [217–220]. Co-administration of 
roxithromycin with theophylline resulted in unchanged PK parameters [221].  
Glucocorticoids: A comparative study in 6 patients showed CLR to have no effect on prednisolon 
PK, but resulted in a 65% reduction of methylprednisolon clearance and significantly increased 
methylprednisolon concentrations [222].  
Psychopharmaca: A double-dummy double-blinded cross-over study in 8 healthy subjects found the 
AUC of buspirone to increase by 600% and the Cmax to increase by 500% [223]. ERY was found to 
exhibit no effect on the co-administered agent clozapine [224]. 
Anti-protozoic drugs: In a double-blinded cross-over study in 30 healthy volunteers  
co-administering ERY and quinine, a limited increase of total quinine levels was observed with 
disproportionately increased free quinine levels [225]. This was thought to be caused by irreversible 
inhibition of liver function-dependent CYP3A4-mediated metabolism and a displacement of quinine 
from plasma proteins. No escalated side effects or parasite clearance time was observed when 
spiramycin was combined with quinine [226]. A study of 24 patients concluded there is no PK 
interaction between AZM and chloroquine [154]. 
Anti-epileptics: When phenytoin was administered to patients also receiving josamycin, no PK 
changes were observed compared to monotherapy [217]. Finally, several studies found that ERY 
exhibited no effect on the co-administered agents oxcarbazepine [227], phenytoine [228], or  
tiagabin [229].  
Opioids: Telithromycin combined with oxycodon in a blinded cross-over study resulted in an 
increased oxycodon AUC by 80% and a decreased AUC of the metabolite noroxycodon by 46% [230].  
Antihelmintic drugs: A cross-over study of 18 volunteers found an increase of ivermectin AUC of 
31% and Cmax of 27% possibly by competition of AZM and ivermectin with P-gp, when combining 
AZM with albendazole and ivermectin [231].  
Various: A comparative interaction study in 12 patients showed that CLR had no effect on dapsone 
PK [111], and a study without a clear study design of 12 HIV-positive patients found no differences in 




PK of 2’-3’-dideoxynosine either [129]. Cabergoline PK was studied in 10 healthy volunteers and  
7 Parkinson patients after co-administration of CLR. This resulted in an increase of both the AUC and 
Cmax of cabergoline by 260% in healthy volunteers and by 170% in Parkinson patients [232]. When 
ERY was co-administered with roflumilast, the AUC of the latter increased by 70% in an open-label 
single-dose comparative study of 16 healthy subjects [233]. Several studies found that ERY exhibited 
no effect on the co-administered agent, i.e., acetaminophen [234], desmopressin (except for shortening 
tmax) [235], or intranasal levocabastine [236]. AZM or CLR did not exhibit an effect on the PK 
parameters of atorvastatin either [167].  
3.4. Fluoroquinolones  
Fluoroquinolones exhibit their bactericidal effect through complex formation with bacterial  
DNA-gyrase, also known as topo-isomerase I, and with topo-isomerase IV. Interactions of the 
currently available fluoroquinolones (i.e., ciprofloxacin [CIP], levofloxacin [LVX], gatifloxacin 
[GAT], MXF, and ofloxacin [OFX]) with enzyme systems and the effect of food on the PK of 
fluoroquinolones are briefly summarized in Table 4. The articles on which the summary is based are 
further specified in the text. 
Table 4. Summary of interactions of fluoroquinolones with enzyme systems and/or food.  
 Fluoroquinolones *1 
 Ciprofloxacin Levofloxacin  Gatifloxacin  Moxifloxacin  Ofloxacin Clinafloxacin  Lomefloxacin Grepafloxacin 
Absorption:         
Meal 0-↓ ↓ ↓ ↓ 0 - - - 
Enteral feeding ↓-↓↓*2  0 - ↓ - - - 








- - - - - 
Dairy products ↓ ↓ - 0-↓ - - - - 
Di-/trivalent 
metallic agents 
↓-↓↓ 0-↓ - 0-↓ ↓-↓↓ - - - 
Metabolism: - - - - - - - - 
Phase II enzymes - - - S - - - - 
CYP1A2 ↓-↓↓↓ - 0 0 0 ↓↓ 0 ↓↓ 
CYP3A4 0 0 - 0 - - - - 
Excretion:         
Competitive 
tubular filtration 
# # # - - - - - 
P-gp 0 - - - - - - - 
*1 Arrows pointing downward (↓) indicate inhibition and upward (↑) induction. The number of arrows indicates the extent of the 
inhibition or induction: 1 arrow <50%, 2 arrows 50–150%, 3 arrows >150% increase/decrease of AUC. “S” indicates the drug being a 
substrate, “0” indicates the absence of an interaction, an “#” indicates the presence of an interaction. *2 Depending on method of 
administration, i.e., oral, through jejunostomy or through gastrostomy tubes.  
Since there were no interactions affecting displacement/distribution this process was not included in the table. 




3.4.1. Fluoroquinolones as Victims 
Food: Several randomized cross-over studies have focused on bioavailability of fluoroquinolones 
when co-administered with food. Co-administration of a CIP suspension with a standard lunch had 
little effect on CIP PK parameters, reducing the Cmax by 11% and increasing the AUC by 13% 
compared to a fasted state, in a randomized cross-over study of 68 healthy volunteers [237]. A 
comparable four-way cross-over study that included 6 healthy volunteers showed that intake with food 
had no effect on OFX PK parameters [238]. Enteral feeding reduced the Cmax and AUC of CIP, 
depending on the method of administration, i.e., orally (by 43% and 27% respectively), through 
gastrostomy tubes (by 37% and 53% respectively), or through jejunostomy (by 59% and 67% 
respectively) [239,240]. Both Cmax and AUC of CIP were reduced by approximately 20% when  
co-administered with orange juice and by approximately 40% in case of concomitant treatment with 
calcium-fortified orange juice [241]. Dairy products, e.g., milk and yogurt, reduced the CIP exposure 
by 30% and 36% respectively when co-administered [242]. The OFX Cmax and AUC were reduced by 
co-administration with enteral feeding by respectively 36% and 10% [240]. The relative bioavailability 
of GAT crushed tablet suspension was 99–109% when co-administered with enteral feeding in  
16 patients [243]. Calcium-fortified orange juice slightly reduced the GAT Cmax by 15%  
(non-significant) and the AUC by 12% [244], and a light morning meal appeared to have no effect on 
GAT Cmax and reduced the AUC negligibly by 12% [245].  
A high-fat breakfast combined with LVX in 24 healthy volunteers reduced the LVX Cmax by 14% 
and the AUC by 10% [246]. However, in a randomized open-label 3-way cross-over study where LVX 
was co-administered with juice and cereal with and without milk, the AUC was reduced by 
approximately 15% [247]. Calcium-fortified orange juice reduced the LVX Cmax by 18% without an 
effect on the AUC [248].  
Crushed MXF could be administered with food via a nasogastric tube, resulting in a reduced Cmax 
by 12% without effect on the AUC [249]. Co-administration of MXF together with dairy products is 
also possible, as yogurt reduced the Cmax and AUC by 15% and 6% respectively [250]. 
Di- and trivalent metallic agents: Several studies focused on interactions between di- and trivalent 
metallic agents and fluoroquinolones. The proposed mechanism is that of a chelation complex 
formation with di- and trivalent metallic agents. When 600 mg iron (as gluconate) is co-administered 
with CIP in eight healthy volunteers, the Cmax is reduced by 57% and the AUC by 67% [251]. In the 
same study, 300 mg iron (as sulphate) reduced these PK parameters by respectively 33% and 46%. A 
different study co-administering 100 mg ferrous sulphate with CIP or OFX found a decrease of Cmax 
and AUC of respectively 54% and 57% for CIP, and of 36% and 25% for OFX [252]. Ferrous sulphate 
in a dose of 100 mg reduced the Cmax of MXF by 59% and the AUC by 39% [253]. Also, lomefloxacin 
appeared to have an interaction with iron and resulted in reducing the Cmax of lomefloxacin  
by 26% [254]. 
When Ca2+ was co-administered with CIP or gemifloxacin, fluoroquinolone exposure decreases and 
separated administration may be warranted as Ca2+ reduced CIP Cmax and AUC by 48% [255], and 
reduced the gemifloxacin AUC by 21% and the Cmax by 17% [256]. Remarkably, although the AUC 
remained unchanged, the Cmax of LVX [257] and the third-generation fluoroquinolone MXF [258] 




decreased by approximately 18% by means of concomitant treatment with calcium. Probably a less 
stable chelating complex is formed in the latter case [258].  
No clinical relevant changes in drug exposure—possibly through a less stable chelating complex—
was found after administration of Al3+ with OFX in 10 healthy volunteers either [259]. A case control 
study suggested that di- and trivalent cation-containing compounds (DTCCs), including multivitamins, 
might inhibit fluoroquinolone absorption [260]. Also interactions with OTC preparations such as 
Centrum Forte®, containing Fe2+, Mg2+, Zn2+, Ca2+, Cu2+ and Mn2+, are observed, resulting in a 
decrease in Cmax and AUC by 55% [251]. Finally, concomitant treatment with sevelamer 
hydrochloride, a phosphate-binding polymer, with CIP should be avoided as it reduced the CIP Cmax by 
40% and the AUC by 52% in 15 healthy volunteers [255]. This is also the case for concomitant 
treatment of CIP with lanthanum carbonate, which reduces both the CIP AUC and Cmax by 55% [261]. 
Gastric acid-reducing agents: Maalox®, an antacid containing Mg2+ and Al3+, was combined with 
CIP [262], OFX [263], GAT [264], and MXF [265] in several studies, resulting in a clinically relevant 
reduction of absorption for all fluoroquinolones except for OFX. Maalox® reduces CIP Cmax after  
5–10 min, 2 h and 4 h by 80%, 74%, and 13% respectively, and the CIP AUC by 85%, 77%, and 30% 
respectively [262]. GAT concomitantly administered with Maalox® reduced the Cmax by 68% and AUC 
by 64%, but when Maalox® was administered 2h prior to GAT, the Cmax was reduced by 45% and the 
AUC by 42% [264]. Co-administration of MXF with Maalox® resulted in a reduced Cmax when the 
antacid is administered simultaneously, 4h prior, or 2h after MXF, by respectively 61%, 1%, and 7%, 
and reduced AUC by 59%, 23%, and 26% at the aforementioned time points [265]. As an alternative 
for Maalox®, ranitidine is recommended. Co-administration of ranitidine with CIP [262] results in 
relatively unchanged Cmax and AUC by 15%, and a combination with MXF [265] results in an 
increased Cmax by 3% and an AUC by 8%. CIP treatment with concomitant omeprazole seems to be 
possible since a PK interaction is of non-significance for immediate release tablets [266] and extended-
release tablets [267]. Sucralfate, containing Al3+, should not be concomitantly administered with CIP, 
LVX, OFX, or MXF. Four grams of sucralfate [268,269] reduced the AUC of CIP by 88–96% and  
1 gram [270] by 30% when administered simultaneously. Sucralfate (1 g) also reduced the Cmax and 
AUC of OFX [238,271] by respectively 70% and 61%, and of MXF [253] by respectively 71% and 
60%, but did not affect LVX [246] PK parameters in a clinical relevant matter. Pepto Bismol®, 
containing Bi3+ and Al3+, did not reduce the drug exposure of CIP significantly, resulting in a decrease 
of Cmax by 14% and AUC by 12% [272]. 
Antiretroviral drugs: The antiretroviral drug didanosine is unstable in an acidic environment and is 
kept stable by incorporating a buffer containing dihydroxylaluminium sodium carbonate and 
magnesium hydroxide in the formulation. These excipients interact with CIP and consequently result 
in a reduced Cmax of CIP by 16–93% and AUC by 26–98% [273,274]. A new enteric bead formulation 
of didanosine allows concomitant administration with CIP, resulting in a reduced Cmax and AUC of 
approximately 9% [274,275].  
Anti-TB drugs: RFP modestly reduced MXF exposure by 17% and reduced the elimination half-life 
from 11.1 to 8.9 hours, possibly by inducing phase-II enzymes [43]. However, a PK interaction 
between RIF and MXF was observed in two prospective cohort studies [106,107]. RIF decreased MXF 
exposure by approximately 30%, possibly through induction of P-gp [107] combined with phase-II 
sulphatation and glucuronidation [106]. 




Anti-protozoic drugs: Co-administration of chloroquine with CIP increased the cumulative urinary 
concentration and excretion rate of CIP [276] and reduced the Cmax by 22% [277] in five healthy male 
volunteers. 
Analgesic: When CIP is co-administered with oral phenazopyridine, the CIP AUC increased by 
30% and the tmax increased from 1h to 1.5h, but the Cmax remained unchanged [278]. Competition for 
glomular filtration is a proposed mechanism. 
Cardiaca: LVX has been suggested to inhibit metabolism of digoxin by intestinal bacteria to 
inactive metabolites which are subsequently excreted in urine and faeces, based on its broad 
antibacterial activity [279,280]. However, a clinically relevant interaction between digoxin and LVX 
was not observed [279]. For the newer fluoroquinolones sparfloxacin [281] and gemifloxacin [282] no 
clinically relevant interaction was observed with concomitant digoxin administration either. 
Antigout drugs: Probenecid may possibly compete with fluoroquinolones for tubular secretion.  
Co-administration with CIP [283,284] and gemifloxacin [285] resulted in an increased drug exposure. 
Although the affinity for the renal transporter is greater for CIP and gemifloxacin than for probenecid, 
drug levels more than 100 times higher are observed for CIP and gemifloxacin.  
3.4.2. Fluoroquinolones as Perpetrators 
Psychopharmaca: Several fluoroquinolones appear to inhibit CYP1A2, albeit to different extents. 
Drugs undergoing biotransformation through CYP1A2, such as caffeine by 3-N-demethylation, are at 
risk of interacting with fluoroquinolones [286]. Caffeine drug exposure has been increased by CIP, 
with an increase in Cmax varying between 7–17% and an AUC increase ranging from 17 to 58%, 
depending on the CIP dose (200–1000 mg) in a prospective cohort study (n = 12) [287]. The same 
study found that OFX had negligible influence on caffeine PK parameters. Another study observed an 
increase in AUC and terminal phase half-life of caffeine by 145% and 115% respectively when  
co-administered with 1500 mg CIP [288]. The authors recommended that patients receiving CIP 
restrict their intake of caffeine. Of the newer fluoroquinolones, co-administration of clinafloxacin 
appeared to reduce caffeine clearance by 84%. As a result, the authors advised patients receiving 
clinafloxacin to restrict their caffeine intake [289]. Lomefloxacin, however, appeared not to have a 
significant effect on the caffeine disposition of 16 young healthy volunteers [290]. 
CIP was observed to induce clozapine and its metabolite N-desmethylclozapine serum concentration 
through CYP1A2 inhibition by approximately 30% in a randomized double-blinded cross-over study 
of 7 patients [291]. Several case reports suggest CIP exhibits a drug interaction with olanzapine, 
probably through CYP1A2 inhibition, resulting in QT prolongation [292,293]. 
Bronchodilators: Theophylline is also a CYP1A2 substrate. Therefore, patients receiving this agent 
are at risk for a drug-drug interation of theophylline with several fluoroquinolones. CIP, in a dose of 
1000 mg, reduced theofylline clearance by 19–32% [216,294–298], whereas 600mg OFX  
co-administrated with caffeine led to unchanged theophylline disposition [299]. Co-administration of 
GAT [300] and MXF [301] with theophylline did not result in clinically relevant changes in PK 
parameters either. Of the newer fluoroquinolones, clinafloxacin or grepafloxacin changed theophylline 
PK parameters. Grepafloxacin (600 mg) significantly increased theophylline AUC and Cmax, and 
reduced theophylline clearance by 50% in 12 healthy volunteers [302]. Clinafloxacin reduced 
theophylline clearance dose-dependently by 50% (200 mg clinafloxacin) and 70% (400 mg 




clinafloxacin) [289]. However, lomefloxacin, gemifloxacin, sparfloxacin, and trovafloxacin appeared 
to have minimal effect on PK parameters of theophylline [298,303–305]. 
Anesthetics: CIP appeared to exhibit an interaction with anesthetics ropivacaine and lidocaine as 
well by means of CYP1A2 inhibition, resulting in an increased anesthetic exposure. CIP increased 
lidocaine AUC by 26% and Cmax by 12% in a randomized double-blinded cross-over study of  
9 patients [306]. In a similar study, CIP was found to reduce the clearance by 31%, without a 
significant effect on ropivacaine AUC and Cmax [307]. LVX [308] and OFX increased the drug 
exposure of procainamide, probably through competition for tubular secretion through the organic 
cation transporter, resulting in significantly decreased renal clearance. When CIP was co-administered 
with procainamide, only the renal clearance of procainamide and its metabolite N-acetylprocainamide 
decreased significantly, leaving the other PK parameters unchanged [308]. 
Muscle relaxants: CIP was found to greatly increase the AUC and Cmax of tizanide, a centrally 
acting muscle relaxant that is metabolized mainly by CYP1A2, by 874% and 583% respectively [309]. 
Because of escalated hypotensive and sedative effects of tizanide, physicians should avoid concomitant 
administration. 
Immunosuppressants: Despite CYP3A4 involvement in the metabolism of cyclosporine, when CIP 
[310], MXF [311], or LVX [312], are co-administered with cyclosporine, no significant changes in 
cyclosporine exposure are observed in healthy volunteers [310,312] or patients [311]. The PK 
parameters of tacrolimus also remained unaffected after co-administration with MXF in a prospective 
cohort study that included 11 patients [311]. Inhibition of CYP3A4 by FQs is therefore unlikely. 
Anti-diabetic drugs: Cases are reported of co-administration of fluoroquinolones, e.g., CIP and 
LVX, with different anti-diabetic agents, resulting in (refractory) diabetes, but the potential role of 
CYP3A4 is still uncertain and requires further research [313–315]. 
Anti-epileptic drugs: Clinafloxacin lowered phenytoin clearance by 15% when co-administered, 
possibly through CYP2C19 inhibition, leaving the clinafloxacin PK parameters unchanged [289].  
Opioids: Several cases were reported of CIP co-administration with methadone resulting in QT 
prolongation, with a suggested mechanism being CIP inhibiting the CYP1A2 and 3A4-mediated 
metabolism of methadone [316–318]. 
Antimicrobial drugs: CIP did not have a clinically relevant interaction with RIF, with  
co-administration resulting in a decrease of RIF Cmax by 12% without significant changes in  
AUC [319]. 
Anticoagulants: Co-administration of CIP with ximelagatran, an oral direct thrombin inhibitor that 
is a substrate for P-gp and is not metabolized by the CYP450 enzyme system, resulted in unchanged 
ximelagatran PK parameters [320]. 
3.5. β-Lactams  
Although β-lactams are a relatively old group of antimicrobial drugs, only a few prospective drug 
interaction trials have been performed. Most of our knowledge on drug interactions is therefore based 
on case reports. These reports focus mainly on the CYP3A4 isoenzyme induction by flucloxacillin and 
nafcillin, the effect on the intestinal flora, the effect on (tubular) renal clearance of (co-)medication, 
induction of chemical degradation, and displacement of drugs from serum proteins.  




A summary of the interactions is presented in Table 5. The data suggest that β-lactams have an 
effect on renal clearance of co-medication and vice versa. A possible underlying mechanism is the 
competitive character of this interaction, e.g., the drug with the highest affinity for the renal transporter 
is responsible for reducing renal tubular excretion of the competing drug.  






Piperacillin  Ceftriaxon Imipenem, 
Meropenem 
Other *3 
Absorption: - - - - - - 
Displacement/distribution:       
Precipitation with Ca2+ - - - # - - 
Competitive binding on protein sites - - - ↓ - - 
Metabolism:       
CYP3A4 ↑↑-↑↑↑ - - - - - 
Chemical degradation of aminoglycosids - - ↑ - - - 
Excretion:       
Competitive tubular excretion # # # - - # 
*1 Arrows pointing downward (↓) indicate inhibition and upward (↑) induction. The number of arrows indicates the extent 
of the interaction: 1 arrow <50%, 2 arrows 50–150%, 3 arrows >150%. “#” indicates the presence of an interaction. 
*2 Mostly based on case reports: in need of further research. 
*3 Cefaclor, cephalexin, cefuroxime, cefazolin, and cephradine. 
3.5.1. β-Lactams as Victims 
Antimicrobial drugs: Probenecid has been reported to prolong the half-life and increase serum 
levels of cephalosporins cephradine and cefaclor [321]. Another study showed that probenecid 
prolonged the cefuroxim serum half-life by 63% in 10 healthy volunteers, probably by blocking 
tubular excretion. The beneficial effect is that the time that the concentration of cefuroxim is above the 
MIC90 of the causative pathogen was extended [322]. A recent prospective, non-randomized study 
examined the effect of probenecid on blocking tubular excretion of cefazolin. This study showed that 
probenecid 500 mg given orally 4 times a day enabled a cefazolin dose reduction to 2000 mg once a 
day, instead of 3 times a day, still resulting in therapeutic serum concentrations of cefazolin at steady 
state [323].  
Electrolytes: In 2007, a FDA Medwatch alert described a decreased ceftriaxone recovery at higher 
calcium concentrations in two in vitro experiments carried out in blood subtracted from adult patients 
and umbilical cords. This might be due to formation of a ceftriaxone-calcium complex. The motivation 
for these in vitro studies and the following FDA Medwatch alert was a French case report presenting a 
case of an anaphylactic shock and calcium-ceftriaxone precipitation in a premature newborn. 
3.5.2. β-Lactams as Perpetrators 
Oral anti-coagulants: Several case reports showed a decrease of the international normalized ratio 
(INR) when nafcillin or flucloxacillin is added to warfarin therapy [324–328]. This is suggested to be 




caused by an induction of hepatic CYP3A4 isoenzyme, resulting in an increased metabolism  
of warfarin.  
AMX, with or without clavulanic acid, has been reported to increase the INR when combined with 
anticoagulant agents such as warfarin and acenocoumarol, possibly by reducing vitamin K-producing 
gut flora resulting in vitamin K deficiency [329,330]. An open-label case-control study including 302 
cases concluded that penicillins were associated with a risk of overanticoagulation with an adjusted 
odds ratio of 24.2 (95% confidence interval). Amoxicillin plus clavulanic acid (AMC) should be 
avoided in patients receiving coumarins, or extra monitoring of the INR is recommended. However, a 
systematic prospective evaluation of the interaction between AMC and warfarin in 12 patients found 
that the INR was not modified in patients stable on warfarin therapy, in the absence of any infectious 
or inflammatory syndrome [331].  
Calcium antagonist: A blinded randomized cross-over study of 9 healthy volunteers suggested an 
effect of nafcillin on CYP3A4. When nafcillin is combined with nifedipine, a substrate of CYP3A4, 
the AUC of nifedipine is significantly reduced by 63% and the total plasma clearance increased by 
245% [332]. Another report warned not to combine verapamil with highly protein-bound drugs such as 
ceftriaxone, since these may displace verapamil from its protein-binding sites leading to verapamil 
toxicity [333]. 
Methotrexate (MTX): Case reports described AMX to decrease renal tubular excretion, resulting in 
increased MTX concentrations [334]. The pencillin, oxacillin, has also been reported to increase MTX 
toxicity by reducing renal MTX clearance [335]. Piperacillin showed a similar interaction with drugs 
that are cleared renally, such as MTX [336]. A randomized open-label cross-over study of 10 healthy 
volunteers describes piperacillin to reduce renal and non-renal clearance of flucloxacillin by 
respectively 55% and 34% [337]. A proposed underlying mechanism was the higher affinity of 
piperacillin compared to other drugs, such as flucloxacillin or MTX, for the renal transporter 
responsible for renal tubular excretion resulting in competitive inhibition.  
Antimicrobial drugs: Piperacillin has been shown to reduce half life and increase clearance of 
aminoglycosides in several studies by means of chemical degradation, a reaction believed to be 
dependent on many factors like temperature, contact time, concentration, and combined agents. A 
nucleophilic attack of the β-lactam ring of piperacillin on an amino group of the aminoglycoside 
seemed to be responsible for the drug-drug interaction [338–340]. 
Concomitant administration of mezlocillin with cefotaxime in eight healthy volunteers and five 
patients with end-stage renal disease (ESRD) suggested that the lower cefotaxime doses may prove to 
be adequate in patients with normal renal function with co-administered mezlocillin [341]. Although 
the mechanism of this nonrenal PK interaction is still unclear, the authors suspected the character of 
the interaction to be of metabolic origin [341]. 
Anti-epileptics: Seven case reports described a decreased effect of valproic acid when combined 
with meropenem, resulting in sub-therapeutic valproic acid levels and associated seizures [342–348]. 
Although the mechanism is not fully elucidated, two mechanisms were postulated: firstly the increased 
amount of cofactor uridine diphosphate glucuronic acid (UDPGA), increasing the glucuronidation in 
the liver, and secondly suppression of hydrolysis of the glucuronidated valproic acid in the liver [342]. 
Finally, after 60 hours of oxacillin treatment, the fraction of unbound phenytoin in a hypoalbuminemic 




patient rose insignificantly due to increased phenytoin displacement by oxacillin from the plasma 
protein-binding site [349]. 
Psychopharmaca: In three patients with preexisting or impending hypotension, imipenem has been 
reported to cause an episode of severe transient hypotension when combined with haloperidol. 
Competition of both drugs for the protein-binding site is one of the possible mechanisms responsible 
for an increase in the amount of protein-unbound haloperidol [350]. Finally, a case report suggested 
that co-administration of AMC with venlafaxine may result in serotonic toxicity [351]. 
Various: Imipenem was also described to have an interaction with theophyllin, resulting in drug-
induced seizures in a series of 3 cases [352]. Combining cephalosporins and alcohol was discouraged 
too, since peripheral flush with shock was noticed [353]. Finally, a double-blinded randomized single-
dose cross-over study of 12 healthy volunteers showed that co-administration of cephalexin altered the 
systemic disposition of metformin [354]. The authors concluded that cephalexin inhibits renal tubular 
secretion, increasing the metformin Cmax by 34% and the AUC by 24%. 
4. Conclusions  
This article, presenting an overview of PK studies on drug-drug and drug-food interactions of 
macrolides, fluoroquinolones, rifamycines, oxazolidinones, and β-lactam antimicrobial drugs, can be 
used by physicians and pharmacists in daily practice to assist in preventing and managing PK drug 
interactions of antimicrobial drugs. The interactions presented in this article vary in extent of severity 
and clinical relevance. Potential clinical problems can range from therapeutic failure due to low drug 
exposure to adverse events due to toxic drug concentrations. PK interaction studies in both patients and 
healthy volunteers are included in this article. It has been demonstrated that PK characteristics of drugs 
can differ between healthy volunteers and patients [355]. As a result of an underlying disease, 
physiological changes can influence drug PK, although the mechanism remains to be elucidated. In 
many critically ill patients extracellular fluids have increased, possibly resulting in a higher volume of 
distribution that might affect PK [356]. One should bear in mind that findings in PK interaction studies 
performed in healthy volunteers might not be observed in clinical practice in specific  
patient populations. 
Furthermore, PK interaction studies administering both single doses and multiple doses to study 
subjects were used in this overview. It need hardly be mentioned that multiple-dose studies will reflect 
best clinical practice. This is particularly true for PK interaction studies with biotransformation as 
possible underlying mechanism since induction of enzyme systems might require days to 2–3 weeks to 
develop fully [357]. The interaction may also persist at a similar length of time when the inducing 
agent is stopped. Unlike induction, inhibition of enzyme systems can occur within 2–3 days [357].  
Physicians and pharmacists should also be aware of the fact that some of the included studies used 
doses that are higher or lower than those used in daily clinical practice. Especially in non-linear PK, 
this makes PK interactions difficult to interpret. 
Finally, drug interactions not only occur when two or more interacting drugs are administered, but 
can also surface when one of the interacting drugs is halted. Most electronic health record systems 
include a program that can routinely check for drug-drug interactions and could assist in preventing 
drug interaction-related adverse events. However, these programs rarely check for interactions that can 
occur when one of the interacting drugs is halted. Multidisciplinary vigilance of physicians, 




pharmacists, and other health care professionals remains necessary for adequate management of  
drug-interactions of antimicrobial drugs. 
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